Key result
Elevated TAFI levels are linked to higher functional class in stable angina over 1 year.
Why the study?
Impairment of endogenous fibrinolysis is considered a component of residual atherothrombotic risk, yet data regarding thrombin-activable fibrinolysis inhibitor (TAFI) in chronic coronary syndromes remain inconsistent.
Are elevated levels of thrombin-activatable fibrinolysis inhibitor (TAFI) and related hemostatic factors associated with functional class and one-year clinical outcomes in patients with stable angina?
Cohort
Are elevated levels of thrombin-activatable fibrinolysis inhibitor (TAFI) and related hemostatic factors associated with functional class and one-year clinical outcomes in patients with stable angina?
Elevated thrombin-activatable fibrinolysis inhibitor (TAFI) and related hemostatic factors are associated with higher functional classes of stable angina, highlighting the need for prospective validation with standardized endpoints.
Answers are grounded in this paper and cite their sources.
May indicate impaired fibrinolysis in angina severity; hypothesis-generating and requires prospective validation before clinical adoption.
Impairment of endogenous fibrinolysis is considered a component of residual atherothrombotic risk. Data regarding the thrombin-activable fibrinolysis inhibitor (TAFI) in the context of chronic coronary syndromes remain inconsistent. This study aimed to evaluate the levels of TAFI and related hemostatic factors in patients with stable angina, determine their variation across functional classes, and describe the one-year clinical course of a specific subgroup characterized by high TAFI levels. Elevated levels of TAFI and associated hemostatic factors are linked to a higher functional class of stable angina. These findings support the need for prospective validation of TAFI, utilizing individual patient data, standardized clinical endpoints, and multivariable adjustment.
No takes yet. Share an insight, caveat, or question.
М.B. et al. (2026) conducted a cohort in Stable angina pectoris. Elevated thrombin-activatable fibrinolysis inhibitor (TAFI) and related hemostatic factors was evaluated on Variation in TAFI levels across functional classes of stable angina and one-year clinical course. Elevated thrombin-activatable fibrinolysis inhibitor (TAFI) and associated hemostatic factor levels are linked to a higher functional class of stable angina over a 1-year course.
Synapse has enriched 10 related papers. Consider them for comparative context: